Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LATS1 | O95835 | 1/20 | 0.43 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1704061 | 0.91 | LATS1 (0.43) | MAPK1LMNAPOLBMAPTLATS1 | |
| SCHEMBL1704731 | 0.91 | CYP3A4 (0.43) | LMNAPOLBRAB9AMAPTLATS1 | |
| SCHEMBL2953212 | 0.90 | LATS1 (0.43) | LMNAPOLBRAB9AMAPTLATS1 | |
| SCHEMBL1705388 | 0.89 | RAB9A (0.43) | LMNAPOLBRAB9AMAPTLATS1 | |
| SCHEMBL2956022 | 0.89 | MEN1 (0.46) | LMNAPOLBRAB9AMAPTLATS1 | |
| SCHEMBL2952980 | 0.87 | CCNC (0.42) | LMNAPOLBRAB9ALATS1LATS2 | |
| SCHEMBL4635385 | 0.85 | MEN1 (0.40) | MAPK1LMNAPOLBMAPTLATS1 | |
| SCHEMBL4452111 | 0.82 | LATS1 (0.42) | RAB9AMAPTLATS1LATS2KMT2A | |
| SCHEMBL1704411 | 0.80 | MAPT (0.43) | LMNAPOLBRAB9AMAPTLATS1 | |
| SCHEMBL2953461 | 0.79 | MEN1 (0.46) | LMNAPOLBRAB9AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931642-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | Orchid Research Laboratories Limited (IN) | 2008-06-18 | — | — | EP | claimed |
| US-20070072876-A1 | Novel pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2007-03-29 | — | — | US | claimed |
| WO-2007031829-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-22 | — | — | WO | claimed |
| EP-2960341-B1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3263717-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Molecular Health GmbH (DE) | 2018-01-03 | — | — | EP | disclosed |
| US-20170315128-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| EP-2435581-B1 | METHODS OF USE OF A NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) | MOLECULAR HEALTH GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-2960341-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Molecular Health GmbH (DE) | 2015-12-30 | — | — | EP | disclosed |
| EP-2492355-B1 | Tissue protective erythropoietin receptor (nepor) and methods of use | MOLECULAR HEALTH GMBH (DE) | 2015-04-08 | — | — | EP | disclosed |
| US-20140296318-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-8357501-B2 | Tissue protective erythropoietin receptor (NEPOR) and methods of use | MOLECULAR HEALTH GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-20090306186-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG | 2009-12-10 | — | — | US | disclosed |
| EP-2109690-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Alepor GMBH & CO. KG (DE) | 2009-10-21 | — | — | EP | disclosed |
| WO-2009068677-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG (DE) | 2009-06-04 | — | — | WO | disclosed |
| EP-1931642-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | Orchid Research Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| US-20070072876-A1 | Novel pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2007-03-29 | — | — | US | disclosed |
| US-20070072876-A1 | Novel pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2007-03-29 | — | — | US | disclosed |
| US-20070072876-A1 | Novel pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2007-03-29 | — | — | US | disclosed |
| WO-2007031829-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031829-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072876-A1 | Novel pyrimidine carboxamides | UACA, SI, MYLK2 | MAPK1 2448/4885LMNA 2256/4885POLB 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.